Merck to File Vorapaxar, Tredaptive NDAs in 2013; Analysts Unenthused

Drug Industry Daily
A A
Despite the troubled clinical history of Merck’s investigational blood-thinner vorapaxar and cholesterol treatment Tredaptive, the company is planning to file NDAs for the drugs next year.

To View This Article:

Login

Subscribe To Drug Industry Daily